版本:
中国

BRIEF-Sierra Oncology reports preclinical synthetic lethality data for chk1 inhibitor sra737 at aacr

April 3 Sierra Oncology Inc:

* Sierra Oncology Inc - Sierra Oncology collaborator ICR reports preclinical synthetic lethality data for chk1 inhibitor sra737 at aacr

* Sierra Oncology Inc - data supports genetically-driven clinical development strategy Sierra intends to pursue for sra737

* Sierra Oncology Inc - "gemcitabine is known to impair b-family DNA polymerases, further supporting rationale for its clinical combination with sra737." Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐